People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Exicure, Inc. | — | Biotechnology | Series C | $85.9M | $901.1M | 2017 |
| AuraSense Therapeutics, LLC | — | Biotechnology | Series A | $33.6M | $535.0M | 2011 |
C. Shad Thaxton at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside C. Shad Thaxton on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Helen S. Kim | 2 | 6 |
| David R. Walt | 2 | 5 |
| Jay R. Venkatesan | 2 | 3 |
| David S. Snyder | 2 | 3 |
| David A. Giljohann | 2 | 2 |
| Chad Mirkin | 1 | 4 |
| Chad A. Mirkin | 1 | 3 |
| Ekambar R. Kandimalla | 1 | 1 |
| Jay A. Venkatesan | 1 | 1 |
| Percy Shad Van Crocker, Jr. | 1 | 1 |
| Matthias R. Schroff | 1 | 1 |
| David A. Walt | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.